Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease
<p>Abstract</p> <p>Background</p> <p>Morbidity in COPD results from a combination of factors including hypoxia-induced pulmonary hypertension, in part due to pulmonary vascular remodelling. Animal studies suggest a role of angiotensin II and acute studies in man concur....
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2005-08-01
|
| Series: | Respiratory Research |
| Online Access: | http://respiratory-research.com/content/6/1/88 |
| _version_ | 1818682739246759936 |
|---|---|
| author | Shakur B Haleema Phillips Peter G Higham Matthew A Morrell Nicholas W Robinson Paul J Beddoes Ray J |
| author_facet | Shakur B Haleema Phillips Peter G Higham Matthew A Morrell Nicholas W Robinson Paul J Beddoes Ray J |
| author_sort | Shakur B Haleema |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Morbidity in COPD results from a combination of factors including hypoxia-induced pulmonary hypertension, in part due to pulmonary vascular remodelling. Animal studies suggest a role of angiotensin II and acute studies in man concur. Whether chronic angiotensin-II blockade is beneficial is unknown. We studied the effects of an angiotensin-II antagonist losartan, on haemodynamic variables, exercise capacity and symptoms.</p> <p>Methods</p> <p>This was a double-blind, randomized, parallel group, placebo- controlled study of 48 weeks duration. Forty patients with COPD and pulmonary hypertension (Tran tricuspid pressure gradient (TTPG) = 30 mmHg) were randomised to losartan 50 mg or placebo. Changes in TTPG were assessed at 3, 6 and 12 months.</p> <p>Results</p> <p>There was a trend for TTPG to increase in the placebo group (baseline 43.4 versus 48.4 mmHg at endpoint) and stay constant in the losartan group (baseline 42.8 versus 43.6 mmHg). More patients in the losartan group (50%) than in the placebo group (22%) showed a clinically meaningful reduction in TTPG at any timepoint; these effects seemed more marked in patients with higher baseline TTPG. There were no clear improvements in exercise capacity or symptoms.</p> <p>Conclusion</p> <p>In this 12-month pilot study, losartan 50 mg had no statistically significant beneficial effect on TTPG, exercise capacity or symptoms in pulmonary hypertension secondary to obstructive disease. A sub-group of patients with higher TTPG may benefit.</p> |
| first_indexed | 2024-12-17T10:23:38Z |
| format | Article |
| id | doaj.art-471a1721c8ad445582134f682709b4db |
| institution | Directory Open Access Journal |
| issn | 1465-9921 |
| language | English |
| last_indexed | 2024-12-17T10:23:38Z |
| publishDate | 2005-08-01 |
| publisher | BMC |
| record_format | Article |
| series | Respiratory Research |
| spelling | doaj.art-471a1721c8ad445582134f682709b4db2022-12-21T21:52:44ZengBMCRespiratory Research1465-99212005-08-01618810.1186/1465-9921-6-88Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary diseaseShakur B HaleemaPhillips Peter GHigham Matthew AMorrell Nicholas WRobinson Paul JBeddoes Ray J<p>Abstract</p> <p>Background</p> <p>Morbidity in COPD results from a combination of factors including hypoxia-induced pulmonary hypertension, in part due to pulmonary vascular remodelling. Animal studies suggest a role of angiotensin II and acute studies in man concur. Whether chronic angiotensin-II blockade is beneficial is unknown. We studied the effects of an angiotensin-II antagonist losartan, on haemodynamic variables, exercise capacity and symptoms.</p> <p>Methods</p> <p>This was a double-blind, randomized, parallel group, placebo- controlled study of 48 weeks duration. Forty patients with COPD and pulmonary hypertension (Tran tricuspid pressure gradient (TTPG) = 30 mmHg) were randomised to losartan 50 mg or placebo. Changes in TTPG were assessed at 3, 6 and 12 months.</p> <p>Results</p> <p>There was a trend for TTPG to increase in the placebo group (baseline 43.4 versus 48.4 mmHg at endpoint) and stay constant in the losartan group (baseline 42.8 versus 43.6 mmHg). More patients in the losartan group (50%) than in the placebo group (22%) showed a clinically meaningful reduction in TTPG at any timepoint; these effects seemed more marked in patients with higher baseline TTPG. There were no clear improvements in exercise capacity or symptoms.</p> <p>Conclusion</p> <p>In this 12-month pilot study, losartan 50 mg had no statistically significant beneficial effect on TTPG, exercise capacity or symptoms in pulmonary hypertension secondary to obstructive disease. A sub-group of patients with higher TTPG may benefit.</p>http://respiratory-research.com/content/6/1/88 |
| spellingShingle | Shakur B Haleema Phillips Peter G Higham Matthew A Morrell Nicholas W Robinson Paul J Beddoes Ray J Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease Respiratory Research |
| title | Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease |
| title_full | Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease |
| title_fullStr | Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease |
| title_full_unstemmed | Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease |
| title_short | Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease |
| title_sort | pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease |
| url | http://respiratory-research.com/content/6/1/88 |
| work_keys_str_mv | AT shakurbhaleema pilotstudyoflosartanforpulmonaryhypertensioninchronicobstructivepulmonarydisease AT phillipspeterg pilotstudyoflosartanforpulmonaryhypertensioninchronicobstructivepulmonarydisease AT highammatthewa pilotstudyoflosartanforpulmonaryhypertensioninchronicobstructivepulmonarydisease AT morrellnicholasw pilotstudyoflosartanforpulmonaryhypertensioninchronicobstructivepulmonarydisease AT robinsonpaulj pilotstudyoflosartanforpulmonaryhypertensioninchronicobstructivepulmonarydisease AT beddoesrayj pilotstudyoflosartanforpulmonaryhypertensioninchronicobstructivepulmonarydisease |